WO2008006187A3 - Protein complexes for prevention and treatment of diseases with angiogenesis disorders - Google Patents

Protein complexes for prevention and treatment of diseases with angiogenesis disorders Download PDF

Info

Publication number
WO2008006187A3
WO2008006187A3 PCT/BY2007/000002 BY2007000002W WO2008006187A3 WO 2008006187 A3 WO2008006187 A3 WO 2008006187A3 BY 2007000002 W BY2007000002 W BY 2007000002W WO 2008006187 A3 WO2008006187 A3 WO 2008006187A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein complexes
treatment
diseases
angiogenic
angiogenesis disorders
Prior art date
Application number
PCT/BY2007/000002
Other languages
French (fr)
Other versions
WO2008006187A2 (en
Inventor
Aleksey M Olovnikov
Oleg N Darashkevitch
Eugeny I Goufman
Original Assignee
Legeev Yury V
Aleksey M Olovnikov
Oleg N Darashkevitch
Eugeny I Goufman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legeev Yury V, Aleksey M Olovnikov, Oleg N Darashkevitch, Eugeny I Goufman filed Critical Legeev Yury V
Publication of WO2008006187A2 publication Critical patent/WO2008006187A2/en
Publication of WO2008006187A3 publication Critical patent/WO2008006187A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the medical field, and in particular, to protein complexes and application thereof for the correction of autoimmune processes in human or animal bodies and also to a research of biochemical mechanisms of diseases with angiogenesis disorders. The protein complexes claimed comprise an antigen and an effector portion attached thereto wherein said antigen presents an angiogenic factor. An angiogenic factors of a protein complexes could be both pro-angiogenic and anti-angiogenic. An effector portion can either show of immunomodulating activity, or provide the specific influence on a target immunocompetent cells Moreover, it can be made in the form of a polymer carrier for depleting of target autoantibodies and immunocompetent cells. There are also claimed the use of new protein complexes, the new methods of treatment of diseases with angiogenesis disorders and a new method and a new test-system for monitoring of angiogenesis disorders for use in the above methods of treatment. The inventors are emphasizing the role of autoimmune mechanism in origin of malignant growth and the importance of subject of the invention for early cancer diagnostics, prevention and treatment
PCT/BY2007/000002 2006-07-12 2007-07-12 Protein complexes for prevention and treatment of diseases with angiogenesis disorders WO2008006187A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
BY20060719 2006-07-12
BYA20060719 2006-07-12
BY20060916 2006-09-20
BYA20060916 2006-09-20
BYA20061352 2006-12-28
BY20061352 2006-12-28
BY20070027 2007-01-12
BYA20070027 2007-01-12

Publications (2)

Publication Number Publication Date
WO2008006187A2 WO2008006187A2 (en) 2008-01-17
WO2008006187A3 true WO2008006187A3 (en) 2009-02-12

Family

ID=38805594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BY2007/000002 WO2008006187A2 (en) 2006-07-12 2007-07-12 Protein complexes for prevention and treatment of diseases with angiogenesis disorders

Country Status (1)

Country Link
WO (1) WO2008006187A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2268301B1 (en) * 2008-01-24 2020-02-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
JP2012136437A (en) * 2009-04-10 2012-07-19 Fujifilm Corp Heterocyclic 5-membered ring compound
CN110105362B (en) * 2019-05-29 2020-10-23 威海中腾医药科技有限公司 Safe and green folic acid synthesis method catalyzed by heteropoly acid
AU2021260149A1 (en) * 2020-04-20 2022-09-29 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114685A (en) * 1994-11-09 1996-01-10 北京医科大学 Human interleukin-2 immunotoxin
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
US6451312B1 (en) * 1992-03-05 2002-09-17 Board Of Regents, The University Of Texas System VEGF-gelonin for targeting the vasculature of solid tumors
WO2003106487A1 (en) * 2002-06-17 2003-12-24 Protherics Plc Immunogenic conjugates
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2006031353A2 (en) * 2004-08-16 2006-03-23 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451312B1 (en) * 1992-03-05 2002-09-17 Board Of Regents, The University Of Texas System VEGF-gelonin for targeting the vasculature of solid tumors
CN1114685A (en) * 1994-11-09 1996-01-10 北京医科大学 Human interleukin-2 immunotoxin
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
WO2003106487A1 (en) * 2002-06-17 2003-12-24 Protherics Plc Immunogenic conjugates
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2006031353A2 (en) * 2004-08-16 2006-03-23 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOTZ HUBERT G ET AL: "Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.", JOURNAL OF GASTROINTESTINAL SURGERY, vol. 6, no. 2, March 2002 (2002-03-01), pages 159 - 166, XP002492441, ISSN: 1091-255X *
KRAUSS JÜRGEN ET AL: "Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme", BRITISH JOURNAL OF HAEMATOLOGY, vol. 128, no. 5, 1 March 2005 (2005-03-01), pages 602 - 609, XP002463022, ISSN: 0007-1048 *
RAMAKRISHNAN S ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR-TOXIN CONJUGATE SPECIFICALLY INHIBITS KDR/FLK-1-POSITIVE ENDOTHELIAL CELL PROLIFERATION IN VITRO AND ANGIOGENESIS IN VIVO", CANCER RESEARCH, vol. 56, no. 6, 1 January 1996 (1996-01-01), pages 1324 - 1330, XP001247100, ISSN: 0008-5472 *
WILD R ET AL: "INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH BY VEGF121-TOXIN CONJUGATE: DIFFERENTIAL EFFECT ON PROLIFERATING ENDOTHELIAL CELLS", BRITISH JOURNAL OF CANCER, vol. 83, no. 3, 1 January 2000 (2000-01-01), pages 1077 - 1083, XP002408273, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
WO2008006187A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
FR22C1052I2 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN THE TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES
EP3351558A3 (en) Material and methods for treating or preventing her-3 associated diseases
WO2011143318A3 (en) Anti-fgfr2 antibodies
WO2012061835A3 (en) Apparatus and method for non-invasively detecting diseases that affect structural properties in biological tissues
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
BRPI0818191A2 (en) methods for the formation of vessels from a placental perfusate cell population and for the treatment of an individual having a heart or vascular disease, disorder, condition or insulin
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
EP2987807A3 (en) Antibodies recognising phospho-tau
ATE540709T1 (en) IMPLANTABLE MEDICAL DEVICE WITH PARTICLE COATING
WO2006128742A3 (en) Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide
WO2014183066A3 (en) Protein modification of living cells using sortase
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2008060777A3 (en) Elisa for vegf
EP4289355A3 (en) Continuous analyte measurement system
WO2007028123A3 (en) Cochlear implant fitting
WO2011050344A3 (en) Cancer immunotherapy and method of treatment
EP4005475A4 (en) Non-invasive blood glucometer and blood glucose detection method
WO2012082494A3 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
HK1139878A1 (en) Method for the treatment of biological tissue of animal or human origin, such as porcine or bovine pericardium or human cadaver heart valves, and biological tissue treated accordingly
EP2478901A3 (en) Neurogenic compounds
EA201171232A1 (en) METHOD OF POLYPEPTIDE TRANSFER IN CELLS
WO2008006187A3 (en) Protein complexes for prevention and treatment of diseases with angiogenesis disorders
WO2010034514A3 (en) Cfhr1 as a c5 convertase inhibitor for the treatment of autoimmune diseases
CY1114811T1 (en) NEW FRACTIONS OF PROTEIN MILK AND THEIR USE FOR PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07800404

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07800404

Country of ref document: EP

Kind code of ref document: A2